Isomorphic Labs closed a $2.1 billion Series B to scale its AI drug-discovery engine and push more programs toward clinical entry. The round, described as a major milestone for AI-first drug design, followed Isomorphic’s earlier funding and was backed by a group that included Alphabet’s ecosystem interests. The company said the funding will support development and deployment of its unified drug design model stack, including IsoDDE, and accelerate its internal pipeline into the clinic. The announcement framed the investment as confidence in a platform that has already produced collaboration deals with large pharma. For the biotech market, the size of the round reinforces continued investor appetite for AI-enabled modalities, even as clinical-risk pressure persists across the broader sector. It also may intensify competition for partnerships where model-generated chemistry can translate into tradable candidates and differentiated mechanisms. With AI drug-discovery funding again reaching ten figures, follow-through will likely depend on pipeline progress, rate of candidate selection and the quality of data supporting early clinical packages.